Core Viewpoint - Butterfly Network, Inc. is set to participate in the 44th Annual J.P. Morgan Healthcare Conference scheduled for January 12-15, 2026, in San Francisco, California [1]. Company Participation - The company's leadership team, including Joseph DeVivo (President, CEO & Chairman) and John Doherty (Executive Vice President & CFO), will represent Butterfly Network at the conference [1].

Core Insights - Artificial intelligence (AI) is identified as the greatest investment opportunity of the current era, with a strong emphasis on the urgency to invest now [1][13] - The energy demands of AI technologies are significant, with data centers consuming as much energy as small cities, leading to concerns about power grid strain and rising electricity prices [2][3] Investment Opportunity - A specific company is highlighted as a critical player in the AI energy sector, owning essential energy infrastructure assets that are poised to benefit from the increasing energy demands of AI [3][7] - This company is not a chipmaker or cloud platform but is positioned as a "toll booth" operator in the AI energy boom, collecting fees from energy exports [5][6] Financial Position - The company is noted for being debt-free and holding a substantial cash reserve, amounting to nearly one-third of its market capitalization, which provides a strong financial foundation [8][10] - It is trading at less than 7 times earnings, indicating a potentially undervalued position in the market compared to its peers [10] Market Trends - The company is strategically aligned with trends such as the onshoring boom driven by tariffs and the surge in U.S. LNG exports, positioning it favorably within the energy sector [14][5] - The influx of talent into the AI sector is expected to drive continuous innovation and advancements, further solidifying the importance of energy infrastructure in supporting AI growth [12][11] Future Outlook - The company is expected to play a pivotal role in the future of clean and reliable power through its nuclear energy assets, which are integral to America's next-generation power strategy [7][14] - The potential for significant returns is highlighted, with projections suggesting a possible 100% return within 12 to 24 months for investors who act now [15][19]

Core Viewpoint - Butterfly Network Inc. (BFLY) is assigned a "Hold" rating due to the market already pricing in the cash-flow benefits from its licensing deal with Midjourney, despite its high valuation and significant write-downs [1]. Financial Analysis - The valuation of Butterfly Network is considered expensive, which raises concerns about its current market position [1]. Strategic Insights - The licensing deal with Midjourney is highlighted as a key factor contributing to Butterfly's cash-flow benefits, indicating potential for future revenue generation [1].

Group 1: Market Movements - Several healthcare and biotech companies experienced notable gains in after-hours trading, driven by clinical updates, recent announcements, and technical rebounds [1] - Kymera Therapeutics Inc. (KYMR) saw a 9.58% increase to $73.00 after hours, following a modest 0.59% rise during the regular session [2] - Ocular Therapeutix Inc. (OCUL) advanced 11.29% to $14.00 after hours, with a 1.21% increase during the day [3] - Guardian Pharmacy Services Inc. (GRDN) shares rose 2.62% to $30.54 in after-hours trading, extending its earlier 1.50% gain [4] - Predictive Oncology Inc. (POAI) jumped 13.62% to $4.84 after hours, recovering from a 22% decline during the regular session [5] - Acumen Pharmaceuticals Inc. (ABOS) edged up 3.23% to $1.92 after hours, following a 6.06% drop during the day [6] - EUDA Health Holdings Ltd. (EUDA) rose 7.72% to $2.93 after hours, recovering from a 6.85% decline earlier [7] - Butterfly Network Inc. (BFLY) gained 4.90% to $3.21 after hours, after finishing the regular session flat [8] Group 2: Company-Specific Updates - Kymera Therapeutics is set to announce results from the BroADen Phase 1b clinical trial of KT-621 for atopic dermatitis on December 8, which has fueled after-hours momentum [2] - Ocular Therapeutix recently announced progress in its HELIOS-3 Phase 3 program for AXPAXLI in diabetic retinopathy, with the first patient randomized on November 24 [3] - Predictive Oncology regained compliance with Nasdaq's minimum stockholders' equity requirement, which has renewed investor confidence [5] - Acumen Pharmaceuticals presented new research at the CTAD conference, highlighting advancements in Alzheimer's treatment [6] - EUDA Health announced a securities purchase agreement for a convertible warrant valued at $100,000, providing financing flexibility for growth initiatives [7]

Butterfly Network (NYSE:BFLY) FY Conference Summary Company Overview - Butterfly Network specializes in medical imaging, particularly handheld ultrasound devices, aiming to democratize access to imaging technology globally [4][10] - The company has developed an innovative ultrasound-on-a-chip technology, allowing for a single device to perform multiple imaging functions, unlike traditional ultrasound machines that require multiple devices for different body parts [8][10] Market Dynamics - The global ultrasound market is valued at approximately $10 billion, with the handheld ultrasound segment estimated at $300-$400 million [20][27] - Currently, handheld devices represent about 40%-50% market share in unit volume, while revenue share is lower due to lower pricing compared to traditional machines [27] - The company aims to position its device as the "stethoscope of the future," promoting widespread adoption among doctors and nurses [13][14] Competitive Landscape - Butterfly Network is competing against established players like GE, with a focus on both traditional ultrasound markets and other handheld devices [27] - The company claims to have a significant market share in developed markets, particularly in medical schools, where it is present in about 70% of institutions [30] Adoption and Innovation - The adoption of handheld ultrasound devices is expected to grow as AI technology improves, making it easier for non-specialists to use ultrasound effectively [15][24] - Butterfly Network is on its third-generation chip, with plans for a fourth-generation chip by late 2026, enhancing image quality and functionality [24] Financial Performance and Projections - The company ended Q3 with $148 million in cash and expects to reduce cash usage from $45 million last year to approximately $40 million this year [33] - Adjusted EBITDA loss is projected to be between $32 million and $35 million, indicating improved financial management [33] - Butterfly Network has set a long-term revenue target of $500 million by 2028, supported by both organic growth and new business opportunities, including partnerships for licensing its semiconductor technology [34][35] Challenges and Future Outlook - The company has faced challenges in hospital sales due to budget constraints and changes in global health funding, but anticipates a recovery in 2026 [31] - The focus on private donors and expanding its market presence in developing countries is seen as crucial for future growth [31] Key Takeaways - Butterfly Network is positioned to disrupt the traditional ultrasound market with its innovative technology and business model, aiming for widespread adoption among healthcare professionals [10][14] - The integration of AI and continuous innovation in imaging technology are critical to overcoming barriers to adoption and enhancing the device's capabilities [15][24] - Financial stability and strategic partnerships will play a significant role in achieving the company's ambitious revenue goals [34][35]

Core Viewpoint - Butterfly Network (BFLY) shares rose by 2.1% following reports of strategic share accumulation by U.S. financier and hedge fund manager Larry Robbins [1] Company Summary - Butterfly Network experienced a 2.1% increase in stock price on Tuesday's late trading session [1] - The rise in share price is attributed to Larry Robbins' strategic increase in ownership of the company's shares [1]

Industry Overview - The healthcare landscape is evolving due to technological advances, policy shifts, and rising patient expectations, marking a pivotal moment for innovation and transformation in the industry [1] - Key trends include precision medicine, AI integration, and enhanced cybersecurity, emphasizing personalized care, operational efficiency, and system-wide resilience [1] Company Performance Tempus AI (TEM) - Tempus reported its first positive adjusted EBITDA of $1.5 million in Q3 2025, driven by strong top-line performance and disciplined operational execution [4][9] - The Genomics business saw a 33% year-over-year volume increase, with Oncology testing growing by 27% and Hereditary testing by 37% [5] - Data Licensing (Insights) business grew by 38% during the quarter, securing $150 million in new total contract value [6] - Cost discipline and efficiency efforts contributed to margin expansion, with adjusted EBITDA potentially reaching $4 million without acquisition-related expenses [7] Butterfly Network (BFLY) - Butterfly Network achieved year-over-year revenue growth while reducing cash burn, with U.S. revenues slightly increasing to $16.1 million [10] - International revenues rose by 4% year-over-year to $5.4 million, driven by higher pricing following the iQ3 launch [11] - The company reported a normalized cash burn of $3.9 million, reflecting improved operational efficiency while still investing in long-term growth areas [12] - Despite a negative adjusted EBITDA loss of $8.1 million and a gross margin of -17.5%, operational improvements were noted [13] Valuation Metrics - Tempus is trading at a forward price-to-sales (P/S) ratio of 8.18, while Butterfly Network's forward sales multiple is 6.45, indicating a discount to Tempus [14] - For 2025, the projected loss per share for Tempus is 65 cents, an improvement from the previous year's loss of $1.58 [15] - Butterfly Network's projected loss per share is 15 cents, compared to a prior-year loss of 34 cents, with stable estimates over the past 30 days [16] Investment Outlook - Tempus is viewed as the stronger investment choice due to its positive adjusted EBITDA and balanced growth across business segments [18] - Butterfly Network, while still not profitable, shows resilience and operational efficiency, making it a potential value play for investors willing to accept higher risk [19]

Core Insights - Premarket trading is showing notable activity with significant price movements indicating potential trading opportunities before the market opens [1] Premarket Gainers - Chijet Motor Company, Inc. (CJET) is up 40% at $2.67 - JX Luxventure Group Inc. (JXG) is up 19% at $4.12 - Inspire Medical Systems, Inc. (INSP) is up 15% at $103.50 - Epsium Enterprise Limited (EPSM) is up 15% at $4.14 - Oscar Health, Inc. (OSCR) is up 12% at $15.13 - Green Dot Corporation (GDOT) is up 11% at $13.21 - Butterfly Network, Inc. (BFLY) is up 6% at $2.82 - Cullinan Therapeutics, Inc. (CGEM) is up 5% at $10.00 - Vir Biotechnology, Inc. (VIR) is up 5% at $5.99 - Nvni Group Limited (NVNI) is up 5% at $3.17 [3] Premarket Losers - Clearside Biomedical, Inc. (CLSD) is down 69% at $0.82 - Twin Hospitality Group Inc. (TWNP) is down 20% at $2.84 - Shuttle Pharmaceuticals Holdings, Inc. (SHPH) is down 15% at $1.35 - Mobile-Network Solutions (MNDR) is down 12% at $4.16 - Waldencast plc (WALD) is down 10% at $2.75 - authID Inc. (AUID) is down 9% at $1.21 - EZGO Technologies Ltd. (EZGO) is down 6% at $1.98 - SciSparc Ltd. (SPRC) is down 5% at $2.34 - Twin Vee Powercats Co. (VEEE) is down 5% at $1.70 - Agape ATP Corporation (ATPC) is down 5% at $1.22 [4]

Core Insights - Biotech and healthcare stocks experienced significant movements in after-hours trading, driven by corporate updates and investor anticipation [1] Company Updates - Butterfly Network, Inc. (BFLY) shares increased by 6.04% to $2.81 after a 14.22% rise to $2.65 at market close, following the announcement of CEO Joseph DeVivo and Interim CFO Megan Carlson's participation in the 8th Annual Evercore Healthcare Conference [2] - Citius Pharmaceuticals Inc. (CTXR) saw a 7.90% increase to $1.23 after a 15.15% rally to $1.14, attributed to a deeper collaboration with Verix for the commercialization of LYMPHIR, an FDA-approved immunotherapy expected to launch in Q4 2025 [3] - ProQR Therapeutics N.V. (PRQR) rose 6.80% to $2.20 after a flat close at $2.06, with no specific news indicating that the movement may be due to investor sentiment [4] - Perrigo Company plc (PRGO) advanced 3.97% to $13.14, building on a 3.10% gain at the close, reflecting steady investor interest despite no new announcements [4] - Tempest Therapeutics, Inc. (TPST) added 4.86% to $3.67 after reversing a decline, following the announcement of plans to acquire CAR-T programs from Factor Bioscience, expected to close in early 2026 [5] - Iterum Therapeutics plc (ITRM) rose 2.77% to $0.3969 after a 4.38% gain at the close, with no new updates released [6] - Processa Pharmaceuticals, Inc. (PCSA) edged up 1.86% to $0.26 despite a steep decline at the close, with no news issued [6]

Core Insights - Butterfly Network, Inc. is participating in the 8th Annual Evercore Healthcare Conference, with key executives scheduled for a fireside chat and one-on-one investor meetings [1][2] - The company is recognized for its innovative Ultrasound-on-Chip™ technology and has launched several handheld ultrasound systems, including the award-winning iQ3 [3][4] Company Overview - Butterfly Network, Inc. is a digital health company focused on transforming medical imaging through handheld, whole-body ultrasound technology and intuitive software solutions [1][3] - The company launched the first handheld, single-probe, whole-body ultrasound system, Butterfly iQ, in 2018, followed by the iQ+ in 2020 and the iQ3 in 2024, each improving in processing power and performance [3] - The iQ3 received the Best Medical Technology award at the 2024 Prix Galien USA Awards, highlighting its significance in the healthcare sector [3] Product and Technology - Butterfly combines advanced hardware, intelligent software, AI, services, and education to enhance the adoption of affordable and accessible imaging solutions [4] - The company’s handheld ultrasound probes, paired with Compass™ enterprise workflow software, have been shown to improve care workflows, reduce costs, and enhance provider economics [4] - Butterfly's devices are available to trained healthcare practitioners globally, addressing critical healthcare challenges [4]